This study will assess the bioavailability of aliskiren and valsartan as a single tablet compared to the same doses of the two drugs given as two separate tablets in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
Novartis Investigative Site
East Hanover, New Jersey, United States
The relative bioavailability of the fixed dose combination of aliskiren/valsartan versus the free combination of aliskiren and valsartan via PK samples at pre-determined time points from pre-dose to 96 hours post-dose.
To characterize the fixed dose combination of aliskiren/valsartan via Pk samples at pre-determines time points.
The safety and tolerability of a single oral dose of a fixed and free combination aliskiren/valsartan.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.